Polaryx Therapeutics, Inc. SEC filings PLYX
Polaryx Therapeutics, Inc. has 35 filings in SEC EDGAR's recent list, going back to Aug 5, 2025. Its latest annual report, Form ARS, was filed on Jul 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 14, 2026 (shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Jul 24, 2026 | — |
| 424B4 | Prospectus | Feb 2, 2026 | — |
| S-1/A | Amended registration statement | Jan 27, 2026 | — |
| S-1/A | Amended registration statement | Jan 14, 2026 | — |
| S-1 | Registration statement | Nov 21, 2025 | — |
Showing 5 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PLYX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- WY
- Headquarters
- Paramus, NJ
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2075320
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.